Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
Ligand Pharmaceuticals (Nasdaq: LGND) has announced it will report its second quarter 2024 financial results after the U.S. financial markets close on Tuesday, August 6, 2024. The company will also hold a conference call at 4:30 p.m. Eastern Time on the same day to discuss the financial results and provide a general business update. Interested parties can join the conference call using the provided phone numbers or access the live and replay webcasts online. This announcement sets the stage for investors and analysts to gain insights into Ligand's financial performance and future outlook.
Ligand Pharmaceuticals (Nasdaq: LGND) ha annunciato che presenterà i suoi risultati finanziari del secondo trimestre 2024 dopo la chiusura dei mercati finanziari statunitensi il martedì 6 agosto 2024. L'azienda terrà anche una conference call alle 16:30, ora orientale dello stesso giorno per discutere i risultati finanziari e fornire un aggiornamento generale sull'andamento dell'attività. Le parti interessate possono partecipare alla conference call utilizzando i numeri di telefono forniti oppure accedere alle webcasts in diretta e in replay online. Questo annuncio apre la strada per investitori e analisti per ottenere informazioni sulle performance finanziarie e le prospettive future di Ligand.
Ligand Pharmaceuticals (Nasdaq: LGND) ha anunciado que reportará sus resultados financieros del segundo trimestre de 2024 después del cierre de los mercados financieros de EE. UU. el martes 6 de agosto de 2024. La compañía también llevará a cabo una conferencia telefónica a las 4:30 p.m., hora del Este el mismo día para discutir los resultados financieros y brindar una actualización general sobre el negocio. Las partes interesadas pueden unirse a la conferencia telefónica utilizando los números de teléfono proporcionados o acceder a las transmisiones web en vivo y a la repetición en línea. Este anuncio proporciona una oportunidad para que los inversores y analistas obtengan información sobre el rendimiento financiero y las perspectivas futuras de Ligand.
리간드 제약 (Nasdaq: LGND)이 2024년 2분기 재무 실적을 미국 금융 시장이 마감한 후인 2024년 8월 6일 화요일에 보고할 것이라고 발표했습니다. 회사는 같은 날 오후 4시 30분 동부 표준시에 재무 실적을 논의하고 일반 비즈니스 업데이트를 제공하기 위해 컨퍼런스 콜을 개최할 것입니다. 관심 있는 분들은 제공된 전화번호를 사용하여 컨퍼런스 콜에 참여하거나 온라인에서 실시간 및 재방송 웹캐스트에 접근할 수 있습니다. 이 발표는 투자자와 분석가들이 리간드의 재무 성과 및 미래 전망에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Ligand Pharmaceuticals (Nasdaq: LGND) a annoncé qu'il publiera ses résultats financiers du deuxième trimestre 2024 après la fermeture des marchés financiers américains le mardi 6 août 2024. L'entreprise tiendra également une conférence téléphonique à 16h30, heure de l'Est le même jour pour discuter des résultats financiers et fournir une mise à jour générale sur l'activité. Les parties intéressées peuvent participer à la conférence téléphonique en utilisant les numéros de téléphone fournis ou accéder aux webdiffusions en direct et aux rediffusions en ligne. Cette annonce ouvre la voie aux investisseurs et aux analystes pour obtenir des informations sur la performance financière et les perspectives futures de Ligand.
Ligand Pharmaceuticals (Nasdaq: LGND) hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 nach dem Schließen der US-Finanzmärkte am Dienstag, den 6. August 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Finanzergebnisse zu erörtern und ein allgemeines Update zum Geschäft zu geben. Interessierte Parteien können an der Telefonkonferenz teilnehmen, indem sie die bereitgestellten Telefonnummern nutzen oder die Live- und Wiederholungs-Webcasts online abrufen. Diese Ankündigung bietet Investoren und Analysten die Möglichkeit, Einblicke in die finanzielle Leistung und die zukünftigen Aussichten von Ligand zu gewinnen.
- None.
- None.
Conference Call and Webcast Information
Date: |
Tuesday, August 6, 2024 |
|
Time: |
4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) |
|
Conference Call: |
(800) 715-9871 ( |
|
(646) 307-1963 (International) |
||
Conference ID is 8755336 |
||
Webcast: |
Live and replay webcasts of the call are available here. |
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Its business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing its technology to help partners discover and develop medicines. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. Ligand’s Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X @Ligand_LGND.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723930890/en/
Investors:
Michael Jeong
investors@ligand.com
(561) 214-4232
LifeSci Advisors
Bob Yedid
bob@lifesciadvisors.com
(516) 428-8577
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
Source: Ligand Pharmaceuticals Incorporated
FAQ
When will Ligand Pharmaceuticals (LGND) report its Q2 2024 financial results?
What time is Ligand's (LGND) Q2 2024 earnings conference call scheduled for?
How can investors access Ligand's (LGND) Q2 2024 earnings call?
What information will be discussed in Ligand's (LGND) Q2 2024 earnings call?
